- Home
- NRIX vs RNP Comparison
NRIX vs RNP Comparison
Compare NRIX & RNP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- RNP
- Stock Information
- Founded
- NRIX 2009
- RNP 2003
- Country
- NRIX United States
- RNP United States
- Employees
- NRIX N/A
- RNP N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- RNP Investment Managers
- Sector
- NRIX Health Care
- RNP Finance
- Exchange
- NRIX Nasdaq
- RNP Nasdaq
- Market Cap
- NRIX 1.1B
- RNP N/A
- IPO Year
- NRIX 2020
- RNP N/A
- Fundamental
- Price
- NRIX $9.64
- RNP $21.41
- Analyst Decision
- NRIX Strong Buy
- RNP
- Analyst Count
- NRIX 17
- RNP 0
- Target Price
- NRIX $30.71
- RNP N/A
- AVG Volume (30 Days)
- NRIX 999.6K
- RNP 117.6K
- Earning Date
- NRIX 04-08-2025
- RNP 01-01-0001
- Dividend Yield
- NRIX N/A
- RNP 7.94%
- EPS Growth
- NRIX N/A
- RNP N/A
- EPS
- NRIX N/A
- RNP N/A
- Revenue
- NRIX $56,417,000.00
- RNP N/A
- Revenue This Year
- NRIX $15.73
- RNP N/A
- Revenue Next Year
- NRIX N/A
- RNP N/A
- P/E Ratio
- NRIX N/A
- RNP N/A
- Revenue Growth
- NRIX N/A
- RNP N/A
- 52 Week Low
- NRIX $8.18
- RNP $15.52
- 52 Week High
- NRIX $29.56
- RNP $21.27
- Technical
- Relative Strength Index (RSI)
- NRIX 36.33
- RNP 54.72
- Support Level
- NRIX $11.05
- RNP $21.32
- Resistance Level
- NRIX $11.56
- RNP $21.75
- Average True Range (ATR)
- NRIX 0.64
- RNP 0.40
- MACD
- NRIX -0.04
- RNP 0.09
- Stochastic Oscillator
- NRIX 18.45
- RNP 78.75
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.